All Pathways
Infectious DiseaseEmergency

Bacterial Meningitis Management (IDSA 2004)

Bacterial Meningitis Management (IDSA 2004): Suspected Bacterial Meningitis → Rapid Clinical Assessment → CT Before LP Indicated? → START Empiric Antibi...

Interactive Decision Tree

Mini Map

Algorithm Steps

  1. Start

    Suspected Bacterial Meningitis

    Fever + headache + neck stiffness, or altered mental status with infectious symptoms

    1. Action

      Rapid Clinical Assessment

      Assess severity and identify contraindications to LP

      • Meningeal signs: Nuchal rigidity, Kernig sign, Brudzinski sign
      • Neurologic exam: GCS, focal deficits, papilledema
      • Signs of sepsis/shock
      • Petechial/purpuric rash (suggests N. meningitidis)
      1. Decision

        CT Before LP Indicated?

        Assess for contraindications to immediate LP

        • CT BEFORE LP if: Immunocompromised, CNS disease history, new-onset seizure, papilledema, altered consciousness, focal neurologic deficit
        • If none present, proceed directly to LP
        1. Action

          START Empiric Antibiotics IMMEDIATELY

          Do NOT delay antibiotics for CT or LP

          • Blood cultures x2 first (if <30 min delay)
          • Dexamethasone 0.15 mg/kg IV q6h BEFORE or WITH first antibiotic dose
          • Empiric antibiotics within 1 hour of presentation
          • Continue dexamethasone x4 days if pneumococcal meningitis
          1. Action

            CT Head (without contrast)

            Evaluate for mass effect, abscess, hemorrhage

            • Give antibiotics BEFORE CT
            • LP after CT if no mass effect/herniation risk
            1. Action

              Empiric Antibiotic Selection by Age

              Based on most likely pathogens

              • Age 2-50: Ceftriaxone 2g IV q12h + Vancomycin 15-20 mg/kg IV q8-12h
              • Age >50 or immunocompromised: ADD Ampicillin 2g IV q4h (for Listeria)
              • Penicillin allergy: Meropenem + Vancomycin (or Chloramphenicol + TMP-SMX)
              • Target vancomycin trough 15-20 mcg/mL
              1. Decision

                CSF Results

                Interpret CSF findings

                • Bacterial: WBC >1000 (PMN predominant), protein >100, glucose <40 (ratio <0.4)
                • Gram stain: 60-90% sensitive if untreated
                • Opening pressure typically >25 cm H2O
                1. Action

                  Gram-Positive Cocci

                  Likely S. pneumoniae

                  • Continue Ceftriaxone + Vancomycin
                  • Narrow when susceptibilities available
                  • If PCN-susceptible: Penicillin G or Ampicillin
                  • Continue dexamethasone x4 days
                  1. Action

                    Treatment Duration & Monitoring

                    Pathogen-specific duration

                    • N. meningitidis: 7 days
                    • H. influenzae: 7 days
                    • S. pneumoniae: 10-14 days
                    • S. agalactiae: 14-21 days
                    • L. monocytogenes: 21 days or longer
                    • Gram-negative bacilli: 21 days
                    1. Warning

                      Watch for Complications

                      Monitor for neurologic and systemic complications

                      • Seizures: ~30% of patients
                      • Cerebral edema/herniation
                      • Hearing loss (especially pneumococcal)
                      • Subdural effusion/empyema
                      • Hydrocephalus
                      • SIADH/cerebral salt wasting
                    2. Outcome

                      Clinical Improvement

                      Defervescence typically within 3-5 days

                      • Repeat LP if no improvement by 48-72 hours
                      • Consider imaging for persistent symptoms
                      • Hearing evaluation before discharge
                    3. Warning

                      Poor Response

                      No improvement or worsening

                      • Repeat LP and imaging
                      • Consider resistant organism
                      • Evaluate for complications (abscess, empyema)
                      • Neurosurgery consultation if needed
                2. Action

                  Gram-Negative Diplococci

                  Likely N. meningitidis

                  • Continue Ceftriaxone (can discontinue vancomycin)
                  • Duration: 7 days
                  • Close contacts: Chemoprophylaxis (rifampin, ciprofloxacin, or ceftriaxone)
                  • Report to public health
                3. Action

                  Gram-Negative Rods

                  Listeria, H. influenzae, or Enterobacteriaceae

                  • GNR: Consider Ceftriaxone + Ampicillin
                  • If Listeria suspected: Ampicillin + Gentamicin
                  • If resistant GNR: Meropenem
                  • Duration: 21 days for Listeria, 7-14 days for others
        2. Action

          Proceed to LP

          No CT contraindications - perform LP immediately

          • Opening pressure measurement
          • CSF: Cell count, protein, glucose, Gram stain, culture
          • Consider: Latex agglutination, PCR panel
          • Blood glucose for CSF:serum ratio

Guideline Source

Practice Guidelines for the Management of Bacterial Meningitis - IDSA 2004

Clinical Safety Information

Clinical Decision Support — Not a Substitute for Clinical Judgment

Individual patient factors may require deviation from these recommendations.

Known Limitations

  • Does not replace clinical judgment - individual patient factors may require deviation
  • Antibiotic choices should be guided by local resistance patterns
  • Does not address pediatric-specific dosing in detail
  • CSF interpretation requires clinical correlation
  • Immunocompromised patients may require broader coverage

Contraindicated Populations

neonatal

Applicable Regions

USEUInternational

EU: Similar approach; consider local pneumococcal resistance patterns

US: Ceftriaxone + vancomycin empiric therapy standard; add ampicillin for Listeria coverage if >50 years

International: Resource-limited settings may require modified approaches based on available antibiotics

Version 1Next review: 2027-01-01

Frequently Asked Questions

What is the Bacterial Meningitis Management (IDSA 2004)?

The Bacterial Meningitis Management (IDSA 2004) is a emergency clinical algorithm for Infectious Disease. It provides a structured decision tree to guide clinical decision-making, based on Practice Guidelines for the Management of Bacterial Meningitis - IDSA 2004.

What guideline is the Bacterial Meningitis Management (IDSA 2004) based on?

This algorithm is based on Practice Guidelines for the Management of Bacterial Meningitis - IDSA 2004 (DOI: 10.1086/425368).

What are the limitations of the Bacterial Meningitis Management (IDSA 2004)?

Known limitations include: Does not replace clinical judgment - individual patient factors may require deviation; Antibiotic choices should be guided by local resistance patterns; Does not address pediatric-specific dosing in detail; CSF interpretation requires clinical correlation; Immunocompromised patients may require broader coverage. Individual patient factors may require deviation from these recommendations.

Get AI-Powered Analysis Alongside This Algorithm

In AttendMe.ai, the Bacterial Meningitis Management (IDSA 2004) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.

Try AttendMe Free